Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of a Multi-dose Regimen of Mebendazole Against Hookworm in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent signed by parents and/or caregiver; and oral assent by participant.~* Able and willing to be examined by a study physician at the beginning of the study.~* Able and willing to provide two stool samples at the beginning (baseline) and approximately three weeks after treatment (follow-up).~* Positive for hookworm eggs in the stool (≥ 100 EPG and at least two Kato-Katz thick smears slides with more than one hookworm egg).~* Absence of major systemic illnesses, e.g. diabetes, severe anemia (HB\<8.0 g/l) as assessed by a medical doctor at school, upon initial clinical assessment.~* No known or reported history of chronical illness as cancer, diabetes, chronic heart, liver or renal disease.~* No recent anthelminthic treatment (within past 4 weeks). No known allergy to study medications (mebendazole and albendazole).~Exclusion Criteria:~No written informed consent by parents and/or caregiver; no oral assent by participant.~* Menarche, based on self-report~* Presence of major systemic illnesses, e.g. diabetes, severe anemia (HB\<8.0 g/l) as assessed by a medical doctor, upon initial clinical assessment.~* History of acute or severe chronic disease.~* Recent use of anthelminthic drug (within past 4 weeks).~* Attending other clinical trials during the study.~* Negative diagnostic result for hookworm eggs in the stool (\< 100 EPG (total of the four slides) and/or only one Kato-Katz thick smear slide with more than one hookworm egg).

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Single dose of mebendazole (Type: ACTIVE_COMPARATOR): In day 1 each child in this treatment arm will receive a 500 mg tablet of mebendazole plus one 100 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the placebo. In day 2 and 3 each child will receive one placebo twice a day (in the morning and in the evening)
- Multiple dose of mebendazole (Type: ACTIVE_COMPARATOR): In day 1 each child in this treatment arm will receive a 100 mg tablet of mebendazole plus one 500 mg placebo tablet in the morning. In the afternoon of day 1 they will only receive the 100 mg tablet of mebendazole. In day 2 and 3 each child will receive one 100 mg tablet of mebendazole twice a day (in the morning and in the evening).

Based on this trial design, predict the completion outcome and termination type (if applicable).